Literature DB >> 10223763

Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer.

H Masuda1, H Aoki.   

Abstract

PURPOSE: To clarify the mechanism of cancer cell invasion, we paid close attention to the role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in normal tissue that is located in the same organ as the cancer.
METHODS: Samples were obtained from a tumor lesion and normal tissue in the resected large intestine of 59 patients with colorectal cancer, including 13 cases with liver metastasis (Group A) and 46 cases without liver metastasis (Group B). In each sample the expression of m-RNA for matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2 was examined using reverse transcription-coupled polymerase chain reaction and southern hybridization.
RESULTS: In normal colon tissue the expression rate of matrix metalloproteinase-2 in Group A (76.9 percent) was significantly higher than that of Group B (15.2 percent; P < 0.0001). Regarding the expression pattern of m-RNA of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue, Group B included 24 cases with matrix metalloproteinase-2 negative, and tissue inhibitor of metalloproteinase-2 positive (24/46; 52.2 percent). Conversely, Group A had only one case with matrix metalloproteinase-2 negative and tissue inhibitor of metalloproteinase-2 positive (1/13; 7.7 percent; P = 0.0107). In addition, the ratio of cases with matrix metalloproteinase-2 positive and tissue inhibitor of metalloproteinase-2 negative in Group A was 30.8 percent (4/13), which was a significantly higher rate than that in Group B (3/46; 6.5 percent; P = 0.0170).
CONCLUSION: We think that the expression pattern of m-RNA of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue is closely related to liver metastasis in colon cancer patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223763     DOI: 10.1007/bf02236360

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

1.  Distinct Transcriptional Changes and Epithelial-Stromal Interactions Are Altered in Early-Stage Colon Cancer Development.

Authors:  Allen Mo; Stephen Jackson; Kamini Varma; Alan Carpino; Charles Giardina; Thomas J Devers; Daniel W Rosenberg
Journal:  Mol Cancer Res       Date:  2016-06-27       Impact factor: 5.852

2.  Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors.

Authors:  Isamu Okamoto; Hiromasa Tsuiki; Lawrence C Kenyon; Andrew K Godwin; David R Emlet; Marina Holgado-Madruga; Irene S Lanham; Christopher J Joynes; Kim T Vo; Abhijit Guha; Mitsuhiro Matsumoto; Yukitaka Ushio; Hideyuki Saya; Albert J Wong
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

3.  Expressions of matrix metalloproteinase-7 and -9 and their prognostic significances in rectal cancer.

Authors:  Young Rak Cho; Hyuk-Chan Kwon; Sung-Hwan Suh; Jong Hoon Lee; Sung-Hyun Kim; Hong-Jo Choi; Hyung-Sik Lee; Mee Sook Roh; Tae-Ho Hwang; Jae-Seok Kim; Hyo-Jin Kim
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

4.  Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium.

Authors:  Deborah L Ornstein; Kenneth H Cohn
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

5.  Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase.

Authors:  H M Collins; T M Morris; S A Watson
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

6.  Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer.

Authors:  Selja Koskensalo; Jaana Hagström; Nina Linder; Mikael Lundin; Timo Sorsa; Johanna Louhimo; Caj Haglund
Journal:  BMC Clin Pathol       Date:  2012-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.